Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.


Journal Article (Review)

Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7-10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.

Full Text

Duke Authors

Cited Authors

  • Strickler, JH; Wu, C; Bekaii-Saab, T

Published Date

  • November 2017

Published In

Volume / Issue

  • 60 /

Start / End Page

  • 109 - 119

PubMed ID

  • 28946014

Pubmed Central ID

  • 28946014

Electronic International Standard Serial Number (EISSN)

  • 1532-1967

Digital Object Identifier (DOI)

  • 10.1016/j.ctrv.2017.08.006


  • eng

Conference Location

  • Netherlands